Developing a treatment to inhibit STAT3 for lung scleroderma
The development of a STAT3 inhibitor for lung scleroderma
This study is looking at a new treatment that could help people with lung scleroderma by targeting a protein called STAT3, which may help reduce lung inflammation and improve breathing and overall well-being.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Altay Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project ID | NIH-10922280 on NIH RePORTER |
What this research studies
This research focuses on creating a new treatment that targets the STAT3 protein, which is known to play a significant role in the progression of lung scleroderma, an autoimmune disorder. By inhibiting STAT3, the research aims to reduce inflammation and fibrosis in the lungs, potentially improving lung function and quality of life for patients. The approach involves studying patient samples and using experimental models to understand how blocking STAT3 can affect disease progression. If successful, this treatment could offer a new therapeutic option for patients suffering from this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with lung scleroderma who are experiencing significant lung-related symptoms.
Not a fit: Patients with scleroderma who do not have lung involvement or those who have already undergone lung transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that slows down or reverses lung damage in patients with scleroderma.
How similar studies have performed: Previous studies have shown promise in targeting STAT3 for treating fibrosis in other conditions, indicating potential success for this approach in scleroderma.
Where this research is happening
San Carlos, UNITED STATES
- Altay Therapeutics, INC. — San Carlos, United States (Active)
Researchers
- Principal investigator: Ozes, Ali Rayet — Altay Therapeutics, INC.
- Study coordinator: Ozes, Ali Rayet
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.